Nanobiotix SA 2022 Annual Report with Sustainability Disclosures
Company: Nanobiotix SA
Sector: Professional & technical services
Country: France
Year: 2022
Type: Annual Report with Sustainability Disclosures
Pages: 320
The report presents Nanobiotix's 2022 clinical-stage biotechnology activities, highlighting progress in NANORAY-312, Study 102, and Study 1100. It reports recommended Phase 2 doses for Study 1100 and pancreatic cancer development, while the Group recognized no revenue in 2022. Its voluntary extra-financial reporting covers patient safety, employee diversity, and health and safety, including 102 employees, 58% women, and three accidents.
Indicators available in this report: